BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial
PurposeThe BRCA1-like profile identifies tumors with a defect in homologous recombination due to inactivation of BRCA1. This profile has been shown to predict which stage III breast cancer patients benefit from myeloablative, DNA double-strand-break-inducing chemotherapy. We tested the predictive po...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
18 August 2017
|
| In: |
Breast cancer research and treatment
Year: 2017, Jahrgang: 166, Heft: 3, Pages: 775-785 |
| ISSN: | 1573-7217 |
| DOI: | 10.1007/s10549-017-4444-9 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1007/s10549-017-4444-9 Verlag, Volltext: https://doi.org/10.1007/s10549-017-4444-9 
|
| Verfasserangaben: | A.G.J. van Rossum, P.C. Schouten, K.E. Weber, V. Nekljudova, C. Denkert, C. Solbach, C.H. Köhne, C. Thomssen, H. Forstbauer, G. Hoffmann, A. Kohls, S. Schmatloch, C. Schem, G. von Minckwitz, T. Karn, V.J. Möbus, S.C. Linn, S. Loibl, F. Marmé |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1581453361 | ||
| 003 | DE-627 | ||
| 005 | 20220815022728.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181001s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10549-017-4444-9 |2 doi | |
| 035 | |a (DE-627)1581453361 | ||
| 035 | |a (DE-576)511453361 | ||
| 035 | |a (DE-599)BSZ511453361 | ||
| 035 | |a (OCoLC)1341019240 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Rossum, Annelot van |e VerfasserIn |0 (DE-588)1168181208 |0 (DE-627)1031818448 |0 (DE-576)511453892 |4 aut | |
| 245 | 1 | 0 | |a BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial |c A.G.J. van Rossum, P.C. Schouten, K.E. Weber, V. Nekljudova, C. Denkert, C. Solbach, C.H. Köhne, C. Thomssen, H. Forstbauer, G. Hoffmann, A. Kohls, S. Schmatloch, C. Schem, G. von Minckwitz, T. Karn, V.J. Möbus, S.C. Linn, S. Loibl, F. Marmé |
| 264 | 1 | |c 18 August 2017 | |
| 300 | |b Diagramme | ||
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 01.10.2018 | ||
| 520 | |a PurposeThe BRCA1-like profile identifies tumors with a defect in homologous recombination due to inactivation of BRCA1. This profile has been shown to predict which stage III breast cancer patients benefit from myeloablative, DNA double-strand-break-inducing chemotherapy. We tested the predictive potential of the BRCA1-like profile for adjuvant non-myeloablative, intensified dose-dense chemotherapy in the GAIN trial.MethodsLymph node positive breast cancer patients were randomized to 3 × 3 dose-dense cycles of intensified epirubicin, paclitaxel, and cyclophosphamide (ETC) or 4 cycles concurrent epirubicin and cyclophosphamide followed by 10 cycles of weekly paclitaxel combined with 4 cycles capecitabine (EC-TX). Only triple negative breast cancer patients (TNBC) for whom tissue was available were included in these planned analyses. BRCA1-like or non-BRCA1-like copy number profiles were derived from low coverage sequencing data.Results119 out of 163 TNBC patients (73%) had a BRCA1-like profile. After median follow-up of 83 months, disease free survival (DFS) was not significantly different between BRCA1-like and non-BRCA1-like patients [adjusted hazard ratio (adj.HR) 1.02; 95% confidence interval (CI) 0.55-1.86], neither was overall survival (OS; adj.HR 1.26; 95% CI 0.58-2.71). When split by BRCA1-like status, DFS and OS were not significantly different between treatments. However, EC-TX seemed to result in a trend to an improvement in DFS in patients with a BRCA1-like tumor, while the reverse accounted for ETC treatment in patients with a non-BRCA1-like tumor (p for interaction = 0.094).ConclusionsThe BRCA1-like profile is not associated with survival benefit for a non-myeloablative, intensified regimen in this study population. Considering the limited cohort size, capecitabine might have additional benefit for TNBC patients. | ||
| 650 | 4 | |a BRCA1-like | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Intensified | |
| 650 | 4 | |a Non-myeloablative | |
| 650 | 4 | |a Profile | |
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breast cancer research and treatment |d Dordrecht [u.a.] : Springer Science + Business Media B.V., 1981 |g 166(2017), 3, Seite 775-785 |h Online-Ressource |w (DE-627)320433722 |w (DE-600)2004077-5 |w (DE-576)104194162 |x 1573-7217 |7 nnas |a BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial |
| 773 | 1 | 8 | |g volume:166 |g year:2017 |g number:3 |g pages:775-785 |g extent:11 |a BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10549-017-4444-9 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10549-017-4444-9 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181001 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 910000 |d 910400 |e 910000PM132561972 |e 910400PM132561972 |k 0/910000/ |k 1/910000/910400/ |p 19 |y j | ||
| 999 | |a KXP-PPN1581453361 |e 302748639X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"family":"Rossum","display":"Rossum, Annelot van","given":"Annelot van","role":"aut"},{"display":"Marmé, Frederik","family":"Marmé","given":"Frederik","role":"aut"}],"id":{"eki":["1581453361"],"doi":["10.1007/s10549-017-4444-9"]},"relHost":[{"disp":"BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trialBreast cancer research and treatment","type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title":"Breast cancer research and treatment","title_sort":"Breast cancer research and treatment"}],"origin":[{"dateIssuedDisp":"1981-","dateIssuedKey":"1981","publisher":"Springer Science + Business Media B.V. ; Kluwer","publisherPlace":"Dordrecht [u.a.] ; Dordrecht [u.a.]"}],"pubHistory":["1.1981 -"],"note":["Gesehen am 02.12.05","Fortsetzung der Druck-Ausgabe"],"id":{"issn":["1573-7217"],"zdb":["2004077-5"],"eki":["320433722"]},"recId":"320433722","physDesc":[{"extent":"Online-Ressource"}],"part":{"volume":"166","extent":"11","text":"166(2017), 3, Seite 775-785","issue":"3","year":"2017","pages":"775-785"},"language":["eng"]}],"recId":"1581453361","physDesc":[{"noteIll":"Diagramme","extent":"11 S."}],"name":{"displayForm":["A.G.J. van Rossum, P.C. Schouten, K.E. Weber, V. Nekljudova, C. Denkert, C. Solbach, C.H. Köhne, C. Thomssen, H. Forstbauer, G. Hoffmann, A. Kohls, S. Schmatloch, C. Schem, G. von Minckwitz, T. Karn, V.J. Möbus, S.C. Linn, S. Loibl, F. Marmé"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial","title_sort":"BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial"}],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"18 August 2017"}],"note":["Gesehen am 01.10.2018"]} | ||
| SRT | |a ROSSUMANNEBRCA1LIKEP1820 | ||